Abstract
Objective
Identify the critical points that lead to recurrences and lack of radicality in endolymphatic sac tumors (ELSTs).
Study design
Retrospective case study and review of the literature.
Setting
Tertiary referral center.
Patients
Thirteen cases of ELST were included in the study and their preoperative, intraoperative and postoperative data were analyzed and compared to a review of the literature.
Intervention(s)
Therapeutical.
Main Outcome Measure(s)
Prevalence of recurrent and residual tumors, comparison to the literature and analysis of ELST characteristics.
Results
Diagnosis was made 26 ± 17 months after the onset of symptomatology, and an ELST was preoperatively suspected in only six cases. At the time of surgery, 10 patients suffered from hearing loss. Preoperative symptoms or audiometry could not predict labyrinth infiltration, although speech discrimination scores were significantly associated with labyrinth infiltration (p = 0.0413). The labyrinth was infiltrated in 8 cases (57.1%), and in 7 cases (46.7%) the tumor eroded the carotid canal, whereas 6 cases (40%) presented an intradural extension. A gross total resection was achieved in 11 cases. There were two residual tumors, one of which because of profuse bleeding, and one recurrence (23.1%). A mean of 22.8% of recurrent or residual tumors are described in the literature based on 242 published cases, in more than half of the cases as a consequence of subtotal tumor resection (STR).
Conclusions
Recurrence derives mostly from the difficulty to identify the extension of the tumor due to the extensive bone infiltration. Accurate diagnosis and correct preoperative planning, with embolization when possible, will facilitate surgery and avoid STR due to intraoperative bleeding. Long follow-ups are important in order to avoid insidious recurrences.
Similar content being viewed by others
References
Corrales CE, Mudry A (2017) History of the endolymphatic sac: from anatomy to surgery. Otol Neurotol 38(1):152–156
Heffner DK (1989) Low-grade adenocarcinoma of probable endolymphatic sac origin. A clinicopathologic study of 20 cases. Cancer 64(11):2292–2302
Barnes L, Eveson JW, Reichart P, Sidransky D (2005) World health organization classification of head and neck tumours. WHO Classif Tumour
Roche PH, Dufour H, Figarella-Branger D, Pellet W (1998) Endolymphatic sac tumors: report of three cases. Neurosurgery 42(4):927–932
Timmer FC, Neeskens LJ, van den Hoogen FJ, Slootweg PJ, Dunnebier EA, Pauw BK, Mulder JJ, Cremers CW, Kunst HP (2011) Endolymphatic Sac tumors: clinical outcome and management in a series of 9 cases. Otol Neurotol 32(4):680–685
Hou ZH, Huang DL, Han DY, Dai P, Young WY, Yang SM (2012) Surgical treatment of endolymphatic sac tumor. Acta Otolaryngol 132(3):329–336
Bastier PL, de Mones E, Marro M, Elkhatib W, Franco-Vidal V, Liguoro D, Darrouzet V (2013) Eur Arch Otorhinolaryngol 270(4):1551–1557
Kim HJ, Hagan M, Butman JA, Baggenstos M, Brewer C, Zalewski C, Linehan WM, Lonser RR (2013) Surgical resection of endolymphatic sac tumors in von Hippel-Lindau disease: findings, results, and indications. Laryngoscope 123(2):477–483
Butman JA, Nduom E, Kim HJ, Lonser RR (2013) Imaging detection of endolymphatic sac tumor-associated hydrops. J Neurosurg 119(2):406–411
Husseini ST, Piccirillo E, Taibah A, Paties CT, Almutair T, Sanna M (2013) The Gruppo Otologico experience of endolymphatic sac tumor. Auris Nasus Larynx 40(1):25–31
Carlson ML, Thom JJ, Driscoll CL, Haynes DS, Neff BA, Link MJ, Wanna GB (2013) Management of primary and recurrent endolymphatic sac tumors. Otol Neurotol 34(5):939–943
Friedman RA, Hoa M, Brackmann DE (2013) Surgical management of endolymphatic sac tumors. J Neurol Surgery, Part B Skull Base 74(1):12–19
Nevoux J, Nowak C, Vellin JF, Lepajolec C, Sterkers O, Richard S, Bobin S (2014) Management of endolymphatic sac tumors: Sporadic cases and von Hippel-Lindau disease. Otol Neurotol 35(5):899–904
Poletti AM, Dubey SP, Colombo G, Cugini G, Mazzoni A (2016) Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. Reports Pract Oncol Radiother 21(4):391–394
Megerian CA, Haynes DS, Poe DS, Choo DI, Keriakas TJ, Glasscock ME (2002) Hearing preservation surgery for small endolymphatic sac tumors in patients with von Hippel-Lindau syndrome. Otol Neurotol 23(3):378–387
Zanoletti E, Girasoli L, Borsetto D, Opocher G, Mazzoni A, Martini A (2017) Endolymphatic sac tumour in von hippel-lindau disease: management strategies. Acta Otorhinolaryngol Ital 37(5):423–429
Le H, Zhang H, Tao W, Lin L, Li J, Ma L, Hong G, Lou X (2019) Clinicoradiologic characteristics of endolymphatic sac tumors. Eur Arch Oto-Rhino-Laryngology 276(10):2705–2714
Thompson LDR, Magliocca KR, Andreasen S, Kiss K, Rooper L, Stelow E, Wenig BM, Bishop JA (2019) CAIX and pax-8 commonly immunoreactive in endolymphatic sac tumors: a clinicopathologic study of 26 cases with differential considerations for metastatic renal cell carcinoma in von Hippel-Lindau patients. Head Neck Pathol 13(3):355–363
Bae SH, Kim S, seob, Kwak SH, Jung JS, Choi JY, Moon IS, (2020) Clinical features and treatment of endolymphatic sac tumor. Acta Otolaryngol 140(6):433–437
Rodrigues S, Fagan P, Turner J (2004) Endolymphatic sac tumors a review of the St.Vincent’s Hospital experience. Otol Neurotol. 25(4):599–603
Hansen MR, Luxford WM (2004) Surgical outcomes in patients with endolymphatic sac tumors. Laryngoscope 114(8I):1470–1474
Schipper J, Maier W, Rosahl SK, van Velthoven V, Berlis A, Boedeker CC, Laszig R, Teszler CB, Ridder GJ (2006) Endolymphatic sac tumours: surgical management. J Otolaryngol 35(6):387–394
Doherty JK, Yong M, Maceri D (2007) Endolymphatic sac tumor: a report of 3 cases and discussion of management. Ear Nose Throat J 86(1):30–35
Diaz RC, Amjad EH, Sargent EW, LaRouere MJ, Shaia WT (2007) Tumors and pseudotumors of the endolymphatic sac. Skull Base 17(6):379–394
Ni Y, Wang S, Huang W, Jiang H, Zhang T, Wang Y, Wang Z, Li H (2008) Surgery for endolymphatic sac tumor: whether and when to keep hearing? Acta Otolaryngol 128(9):976–983
Codreanu C, Tran Ba Huy P (2010) Isolate vertigo crisis revealing an endolymphatic sac tumor. Rom J Morphol Embryol 51(2):387–389
Kawahara N, Kume H, Ueki K, Mishima K, Sasaki TKT (1999) VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease. Neurology 53(1):208
Kim WY, Kaelin WG (2004) Role of VHL gene mutation in human cancer. J Clin Oncol 22(24):4991–5004
Manski TJ, Heffner DK, Glenn GM, Patronas NJ, Pikus AT, Katz D, Lebovics R, Sledjeski K, Choyke PL, Zbar B, Linehan WM, Oldfield EH (1997) Endolymphatic sac tumors: a source of morbid hearing loss in von Hippel- Lindau disease. J Am Med Assoc 277(18):1461–1466
Bausch B, Wellner U, Peyre M et al (2016) Characterization of endolymphatic sac tumors and von Hippel-Lindau disease in the international endolymphatic sac tumor registry. Head Neck. 38(Suppl 1):E673–E679
Bambakidis NC, Megerian CA, Ratcheson RA (2004) Differential grading of endolymphatic sac tumor extension by virtue of von Hippel-Lindau disease status. Otol Neurotol 25(5):773–781
House JW, Brackmann DE (1985) Facial nerve grading system. Otolaryngol - Head Neck Surg 93(2):146–147
Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH (2000) Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene 19(48):5435–5443
Albiñana V, Escribano RMJ, Soler I, Padial LR, Recio-Poveda L, Gómez V, de Las HK, Botella LM (2017) Repurposing propranolol as a drug for the treatment of retinal haemangioblastomas in von Hippel-Lindau disease. Orphanet J Rare Dis 12(1):1–10
Jensen RL, Gillespie D, House P, Layfield L, Shelton C (2004) Endolymphatic sac tumors in patients with and without von Hippel-Lindau disease: the role of genetic mutation, von Hippel-Lindau protein, and hypoxia inducible factor-1α expression. J Neurosurg 100(3):488–497
Bambakidis NC, Rodrigue T, Megerian CA, Ratcheson RA (2005) Endolymphatic sac tumor metastatic to the spine. Case report J Neurosurg Spine 3(1):68–70
Tay KY, Yu E, Kassel E (2007) Spinal metastasis from endolymphatic sac tumor. Am J Neuroradiol 28(4):613–614
Mendenhall WM, Suárez C, Skálová A, Strojan P, Triantafyllou A, Devaney KO, Williams MD, Rinaldo A, Ferlito A (2018) Current treatment of endolymphatic sac tumor of the temporal bone. Adv Ther 35(7):887–898
Prasad SC, Piras G, Piccirillo E, Taibah A, Russo A, He J, Sanna M (2017) Surgical strategy and facial nerve outcomes in petrous bone cholesteatoma. Audiol Neurotol 21(5):275–285
Prasad SC, Laus M, Dandinarasaiah M, Piccirillo E, Russo A, Taibah A, Sanna M (2018) Surgical management of intrinsic tumors of the facial nerve. Neurosurgery 83(4):740–752
Sbaihat A, Bacciu A, Pasanisi E, Sanna M (2013) Skull base chondrosarcomas: surgical treatment and results. Ann Otol Rhinol Laryngol 122(12):763–770
Brackmann DE, Teufert KB (2006) Chondrosarcoma of the skull base: long-term follow-up. Otol Neurotol 27(7):981–991
Sinclair G, Al-Saffar Y, Brigui M, Martin H, Bystam J, Benmakhlouf H, Shamikh A, Dodoo E (2018) Gamma knife radiosurgery in the management of endolymphatic sac tumors. Surg Neurol Int 9:18
Balasubramaniam S, Deshpande RB, Misra BK (2009) Gamma knife radiosurgery in jugular foramen endolymphatic sac adenocarcinoma. J Clin Neurosci 16(5):710–711
Megerian CA, McKenna MJ, Nuss RC, Maniglia AJ, Ojemann RG, Pilch BZ, Nadol JB Jr (1995) Endolymphatic sac tumors: histopathologic confirmation, clinical characterization, and implication in von hippel-lindau disease. Laryngoscope 105(8 Pt 1):801–808
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The study was done at the Gruppo Otologico, a quaternary referral center for neurotology and skull base surgery. There is no conflict of interest involved, and the present work has not received any funding from any sources.
Ethical statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
The study was approved by our Institutional Review Board. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article. However, the article does not contain any direct information regarding patient identity.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sykopetrites, V., Piras, G., Giannuzzi, A. et al. The endolymphatic sac tumor: challenges in the eradication of a localized disease. Eur Arch Otorhinolaryngol 278, 2297–2304 (2021). https://doi.org/10.1007/s00405-020-06323-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-020-06323-x